<DOC>
	<DOCNO>NCT01620476</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial ass safety tolerability liraglutide healthy Japanese male subject .</brief_summary>
	<brief_title>Safety Tolerability Liraglutide Healthy Japanese Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Healthy Japanese Body mass index ( BMI ) 18 27 kg/m^2 inclusive Any clinical laboratory value deviate reference range laboratory Presence diabetes , cancer clinically significant cardiac , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , dermatological , venereal , haematological , neurological , psychiatric disease disorder Hepatitis B surface antigen , Hepatitis C antibody HIV ( human immunodeficiency virus ) antibodies positive History diabetes , cancer clinically significant cardiac , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , dermatological , venereal , haematological , neurological , psychiatric diseases disorder . History significant allergy hypersensitivity Known suspect allergy trial product relate product . History drug alcohol abuse Smokes 15 cigarette , equivalent , per day andis unwilling refrain smoke whenever require trial procedure</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>